FDA Approves Pennsaid Topical Solution
Links shared publicly online about this topic.
- 1,624total visits
FDA Approves Pennsaid Topical Solution
View full resource at drugs.com
Tags: Osteoarthritis Medication, Rheumatoid Arthritis Medication, Mineral, Sodium, FDA, NSAIDs, Voltaren, Cataflam
Most Recently Shared on November 6, 2009 at 12:01 am By:
FDA Approves Pennsaid Topical Solution - http://bit.ly/3judW0
Testosterone topical solution approved for men
endocrinetoday.com — “The FDA has approved testosterone topical solution for replacement therapy in men with certain conditions associated with a deficiency or absence” View full resource at endocrinetoday.com
Most Recently Shared on November 30, 2010 at 4:27 pm By:
Testosterone topical solution approved for men http://bit.ly/h529T2
FDA Approval for Axiron (testosterone) Topical Solution CIII
disabled-world.com — “Axiron topical solution CIII for replacement therapy in men for certain conditions associated with a deficiency or absence of testosterone” View full resource at disabled-world.com
Most Recently Shared on November 27, 2010 at 5:21 pm By:
Disabled World Health Advocate and Health News
FDA Approval for Axiron (testosterone) Topical Solution CIII http://ff.im/-uqxrR
Lilly and Acrux Receive FDA Approval for Axiron (Testosterone) Topical Solution CIII
drugs.com — “Axiron (testosterone) is used to treat conditions associated with a deficiency or absence of testosterone. Includes Axiron side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on November 25, 2010 at 1:11 am By:
Lilly and Acrux Receive FDA Approval for Axiron (Testosterone) Topical Solution CIII - http://bit.ly/fQ5980
Lilly and Acrux Receive FDA Approval for Axiron (Testosterone) Topical Solution CIII
drugs.com — “Axiron (testosterone) is used to treat conditions associated with a deficiency or absence of testosterone. Includes Axiron side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on November 25, 2010 at 1:03 am By:
Drugs and Devices OW OW Health
Lilly and Acrux Receive FDA Approval for Axiron (Testosterone) Topical Solution CIII: INDIANAPOLIS, Ind. a... http://bit.ly/eE8Mq5 #drug
Axiron approved for testosterone deficiency - ONA
oncologynurseadvisor.com — “The FDA has approved Axiron (testosterone topical solution, from Eli Lilly and Acrux) for replacement therapy in men 18yrs for conditions associated with a deficiency or absence of endogenous testosterone.” View full resource at oncologynurseadvisor.com
Most Recently Shared on November 24, 2010 at 4:07 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Axiron approved for testosterone deficiency http://goo.gl/fb/kt67U
Breaking news: FDA approves first once-daily eyedrop for inflammation and pain after cataract surgery - - Drug Topics
drugtopics.modernmedicine.com — “Bromfenac ophthalmic solution (Bromday, ISTA Pharmaceuticals) 0.09% has been granted FDA approval as a once-daily prescription eyedrop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.” View full resource at drugtopics.modernmedicine.com
Most Recently Shared on October 21, 2010 at 2:27 pm By:
Drugs and Devices OW OW Health
Breaking news: FDA approves first once-daily eyedrop for inflammation and pain after cataract surgery: Br... http://bit.ly/cO6qbt #drug
Zymaxid ophthalmic solution approved for bacterial conjunctivitis - ONA
oncologynurseadvisor.com — “The FDA has approved Allergan--™s Zymaxid (gatifloxacin ophthalmic solution) 0.5%, a topical fluoroquinolone, for the treatment of bacterial conjunctivitis caused by susceptible organisms.” View full resource at oncologynurseadvisor.com
Most Recently Shared on May 20, 2010 at 3:23 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Zymaxid ophthalmic solution approved for bacterial conjunctivitis http://goo.gl/fb/sDmLT
Zymaxid ophthalmic solution approved for bacterial conjunctivitis - MPR
empr.com — “The FDA has approved Allergan's Zymaxid (gatifloxacin ophthalmic solution) 0.5%, a topical fluoroquinolone, for the treatment of bacterial conjunctivitis caused by susceptible organisms.” View full resource at empr.com
Most Recently Shared on May 20, 2010 at 3:23 pm By:
Zymaxid ophthalmic solution approved for bacterial conjunctivitis: The FDA has approved Allergan's Zymaxid (gatifl... http://bit.ly/cjMmKJ
Zymaxid ophthalmic solution approved for bacterial conjunctivitis - MPR
empr.com — “The FDA has approved Allergan's Zymaxid (gatifloxacin ophthalmic solution) 0.5%, a topical fluoroquinolone, for the treatment of bacterial conjunctivitis caused by susceptible organisms.” View full resource at empr.com
Most Recently Shared on May 20, 2010 at 2:46 pm By:
MPR News: Zymaxid ophthalmic solution approved for bacterial conjunctivitis: The FDA has approved Allergan's Zymax... http://bit.ly/clFJJU
FDA approves ZYMAXID ophthalmic solution for treatment of bacterial conjunctivitis
news-medical.net — “Allergan, Inc. today announced that the United States Food and Drug Administration has approved ZYMAXID (gatifloxacin ophthalmic solution) 0.5%, a topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms; Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumonia.” View full resource at news-medical.net
Most Recently Shared on May 20, 2010 at 8:27 am By:
Obesity News: FDA approves ZYMAXID ophthalmic solution for treatment of bacterial conjunctivitis: Allergan, Inc.... http://twurl.nl/fcuc3y
PENNSAID(R) Launch Brings New Treatment To Knee Osteoarthritis Patients
medicalnewstoday.com — “Covidien (NYSE: COV), a leading global provider of healthcare products, has introduced PENNSAID® (diclofenac sodium topical solution) 1.5% w/w to the U.S. market. PENNSAID is the only FDA-appr” View full resource at medicalnewstoday.com
Most Recently Shared on April 28, 2010 at 1:11 pm By:
MNT Bones/Orthopedic Health News
PENNSAID(R) Launch Brings New Treatment To Knee Osteoarthritis Patients http://mnt.to/3BPY #bones #orthopedics
Advertisement
